Alder BioPharmaceuticals, Inc. (ALDR) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
11804 NORTH CREEK PARKWAY SOUTH BOTHELL, WA 98011 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2019 MRQ | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 407,369 | 276,240 | 351,867 | 305,172 | 55,872 | |||
| Cash and cash equivalents | 87,865 | 76,896 | 116,216 | 206,492 | 46,795 | |||
| Short-term investments | 319,504 | 199,344 | 235,651 | 98,680 | 9,077 | |||
| Restricted cash and investments | 5,000 | |||||||
| Receivables | 113 | |||||||
| Inventory, net of allowances, customer advances and progress billings | 936 | |||||||
| Inventory | 936 | |||||||
| Other undisclosed current assets | 7,440 | 11,014 | 40,380 | 17,029 | 4,758 | |||
| Total current assets: | 419,809 | 287,254 | 393,183 | 322,201 | 60,743 | |||
| Noncurrent Assets | ||||||||
| Property, plant and equipment | 6,400 | 5,630 | 7,076 | 1,974 | 1,160 | |||
| Long-term investments and receivables | 222 | 865 | 75,840 | |||||
| Long-term investments | 222 | 865 | 75,840 | |||||
| Restricted cash and investments | 10,000 | |||||||
| Other noncurrent assets | 30 | 30 | 8,030 | 12 | 2,456 | |||
| Total noncurrent assets: | 6,430 | 15,882 | 15,971 | 77,826 | 3,616 | |||
| TOTAL ASSETS: | 426,239 | 303,136 | 409,154 | 400,027 | 64,359 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 28,162 | 23,274 | 25,798 | 12,310 | 7,085 | |||
| Employee-related liabilities | 2,211 | |||||||
| Accounts payable | 8,945 | 7,471 | 10,361 | 4,727 | 1,911 | |||
| Accrued liabilities | 19,217 | 15,803 | 15,437 | 7,583 | 2,963 | |||
| Deferred rent credit | 74 | ✕ | ✕ | ✕ | ✕ | |||
| Deferred revenue and credits | ✕ | ✕ | 92 | 92 | 62 | 135 | ||
| Other undisclosed current liabilities | (2,211) | |||||||
| Total current liabilities: | 28,236 | 23,366 | 25,890 | 12,372 | 5,009 | |||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 182,104 | |||||||
| Long-term debt, excluding current maturities | 182,104 | |||||||
| Liabilities, other than long-term debt | 510 | 495 | 481 | 138 | 193 | |||
| Deferred revenue and credits | ✕ | ✕ | 495 | 481 | 138 | 193 | ||
| Deferred rent credit | 510 | ✕ | ✕ | ✕ | ✕ | |||
| Other undisclosed noncurrent liabilities | 1,658 | |||||||
| Total noncurrent liabilities: | 184,272 | 495 | 481 | 138 | 193 | |||
| Total liabilities: | 212,508 | 23,861 | 26,371 | 12,510 | 5,202 | |||
| Equity | ||||||||
| Equity, attributable to parent | 109,976 | 279,275 | 382,783 | 387,517 | 59,157 | |||
| Common stock | 7 | 7 | 5 | 4 | 3 | |||
| Additional paid in capital | 1,074,963 | 946,869 | 761,456 | 610,390 | 196,082 | |||
| Accumulated other comprehensive loss | (1,056) | (92) | (48) | (501) | (22) | |||
| Accumulated deficit | (963,938) | (667,509) | (378,630) | (222,376) | (136,906) | |||
| Other undisclosed equity | 103,755 | |||||||
| Total equity: | 213,731 | 279,275 | 382,783 | 387,517 | 59,157 | |||
| TOTAL LIABILITIES AND EQUITY: | 426,239 | 303,136 | 409,154 | 400,027 | 64,359 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 300 | 1,619 | 113 | 54,705 | |||
| Revenue, net | ✕ | ✕ | 1,619 | 113 | 54,705 | ||
| Gain on disposition of assets for financial service operations | 300 | ✕ | ✕ | ✕ | ✕ | ||
| Cost of revenue (Cost of Goods and Services Sold) | (113) | ||||||
| Gross profit: | 300 | 1,619 | 54,705 | ||||
| Operating expenses | (286,582) | (292,623) | (158,908) | (86,329) | (45,901) | ||
| Other undisclosed operating income (loss) | (300) | 1,050 | |||||
| Operating income (loss): | (286,582) | (291,004) | (157,858) | (86,329) | 8,804 | ||
| Nonoperating income (expense) | (9,625) | 2,768 | 1,789 | 859 | 104 | ||
| Investment income, nonoperating | 8,909 | 2,495 | 1,966 | 702 | 44 | ||
| Gain (loss), foreign currency transaction, before tax | 309 | 223 | (349) | 73 | |||
| Other nonoperating income | 50 | 172 | 84 | 60 | |||
| Interest and debt expense | (17,185) | ||||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 17,185 | ||||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (296,207) | (288,236) | (156,069) | (85,470) | 8,908 | ||
| Loss from equity method investments | (222) | (643) | (185) | ||||
| Income (loss) from continuing operations: | (296,429) | (288,879) | (156,254) | (85,470) | 8,908 | ||
| Income (loss) before gain (loss) on sale of properties: | (296,429) | (288,879) | (156,254) | (85,470) | 8,908 | ||
| Net income (loss) attributable to parent: | (296,429) | (288,879) | (156,254) | (85,470) | 8,908 | ||
| Other undisclosed net loss available to common stockholders, basic | (35,505) | ||||||
| Net income (loss) available to common stockholders, diluted: | (331,934) | (288,879) | (156,254) | (85,470) | 8,908 | ||
Comprehensive Income ($ in thousands)
| 6/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|
| Net income (loss): | (296,429) | (288,879) | (156,254) | (85,470) | 8,908 | ||
| Other comprehensive income (loss) | (964) | (44) | 453 | (479) | (31) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (297,393) | (288,923) | (155,801) | (85,949) | 8,877 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.